Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.Journal of the American Society of Nephrology : JASN · 2020
   Trial
2. Efficacy of Low-Dose Tolvaptan for Treatment of Profound Hyponatremia in Syndrome of Inappropriate Antidiuresis (SIAD): The EFFLUX-FLUID TRIAL.Kidney medicine · 2026
   Article
3. [67/m with impaired consciousness secondary to bronchial carcinoma : Preparation for the medical specialist examination: part 20].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026
   Article
4. [Hyponatremia : Etiology, diagnosis and acute therapy].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023
   Article
5. Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023
   Review
6. Hypertonic Saline Administration via Intraosseous Access During Symptomatic Hyponatremia.Cureus · 2023
   Article
7. Hyponatremia Demystified: Integrating Physiology to Shape Clinical Practice.Advances in kidney disease and health · 2023
   Review
8. Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD).Therapeutic advances in endocrinology and metabolism · 2023
   Review
9. Approach to the Patient: Hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD).The Journal of clinical endocrinology and metabolism · 2022
   Review
10. Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.Endocrine oncology (Bristol, England) · 2022
    Review
11. Management of SIADH-related hyponatremia due to psychotropic medications - An expert consensus from the Association of Medicine and Psychiatry.Journal of psychosomatic research · 2021
    Article

Corrections and comments

• Comment on
  Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as